GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2023-01-09| M&A

Italy’s Chiesi Buys Rare Disease Player Amryt For $1.48 Billion

by Joy Lin
Share To

Italy-based Chiesi Farmaceutici is acquiring Ireland-based Amryt Pharma for $1.48 billion. The deal gives Chiesi a basket of marketed and clinical assets targeting a range of rare diseases. 

Under the deal, Chiesi will purchase Amryt shares at $14.50 per American Depositary Share (ADS), representing a 107% premium of the company’s closing price of $7.00 last Friday. 

Amryt shareholders could also receive Contingent Value Rights (CVR) of up to $2.50 per ADS if Amryt’s product Filsuvez reaches certain milestones. Filsuvez, a designated orphan drug, recently received approval in Europe for the treatment of epidermolysis bullosa (EB), an inherited skin disease.

“Chiesi is aligned with Amryt’s commitment and passion and I believe Chiesi will further maximize the value of Amryt’s current portfolio and pipeline and most importantly, will accelerate our ability to reach more patients in need globally,” said Dr. Joe Wiley, CEO of Amryt, in a statement.

Related Article: GeneOnline’s Pick: Top 10 M&A Deals in 2022

Amryt’s Rare Diseases Portfolio 

Besides Filsuvez, Amryt’s approved treatments include Mycapssa (octreotide), a treatment for acromegaly, metreleptin, a treatment for partial lipodystrophy (PL), and lomitapide, a lipid-lowering medication for familial hypercholesterolemia (HoFH). 

The company is also anticipating the initiation of a Phase 3 clinical study on Mycapssa for neuroendocrine tumors (NET) in the first quarter of 2023. Meanwhile, a Phase 3 trial for the US label expansion for metreleptin in the treatments of PL is currently underway.  

“Amryt has steadily brought innovative products to new markets and, by adding them to the Chiesi portfolio, we hope to make them available to even more patients who may require them,” Marco Vecchia, CEO of Chiesi. 

According to Amryt’s latest financial report released last November, the company earned revenues of $61.1 million in the third quarter of 2022, representing a 8.2% growth from 2021. Full-year financial forecasts range from $260 million to $270 million, representing 17-21% growth. The company’s top selling drug, metreleptin, reached sales of $37.9 million in the third quarter of 2022.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Biotech Showcase 2023: Digital Medicine Innovation: Its Time is Now
2023-02-01
Moving Beyond COVID With mRNA Technology
2023-01-18
JPM23: More Deals as JP Morgan Healthcare Conference 2023 Enters the Third Day
2023-01-12
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
Scroll to Top